Large pharmaceutical firm Novartis confirmed that it is halting and investigating several clinical trial programs involving ...
Earlier this week, it was confirmed that a $380 million partnership between Bristol Myers Squibb (BMS) and contract ...
The organization is nurturing talent alongside NIBRT to fill the region’s many life science manufacturing jobs.
Human-in-the-loop models could provide a credible and scalable path forward for using agentic AI in biopharma commercial ...
Eli Lilly will acquire Merida Biosciences for up to $2.875 billion, gaining MER511, a Phase I therapy targeting ...
Argentine biotech firm Biosidus tripled its cell culture capacity with a $12.9 million expansion to boost biosimilar ...
Large-scale validation of regenerative medicine, especially based on cell therapies, may come from cell therapies developed ...
An expert from CTMC told BioProcess International how recent projects in Houston speak to the city’s drive to become a ...
Learn how strategic CHO cell line development accelerates biologics timelines and supports clinical progression with flexible ...
Bristol Myers Squibb subsidiary RayzeBio has committed to building a radiopharmaceutical manufacturing facility in Whitestown ...
Viral safety is a nonnegotiable regulatory expectation for biologic drug substances manufactured using mammalian cell culture ...
Industry expert Charley Maxwell shares essential strategies for biotech companies navigating Europe's fragmented regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results